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Phenylalanine hydroxylase (PAH) is a liver-specific enzyme involved in the hydroxy- 
lation of phenylalanine (phe) to tyrosine. The deficiency of PAH results in excessive 
accumulation of phe in body fluids that leads to phenylketonuria (PKU). Among 
Caucasians, PKU affects 1 in 10000 live births and the carrier frequency of this 
inherited metabolic disorder is 1 in 50 (Scriver et al 1989). Clinically, this disorder is 
accompanied by neurological impairment and mental retardation of varying degree 
that seem to bear a relationship to the residual PAH activity in these patients (Okano 
et al 1991; Ramus et al 1993). Even though the mechanism of neurological involvement 
is not known at present, it has been observed that regulating the dietary phenylalanine 
intake of PKU patients will minimize their CNS involvement (Matalon and Michals 
1991). The mass screening of newborns in the industrialized world has led to early 
identification and dietary intervention to modulate the outcome of PAH deficiency 
in such individuals. The clinical variation in the severity of PKU is believed to be 
determined by the genotype of the PKU alleles inherited by the affected individuals 
(Okano et al 1991; Ramus et al 1993). 
Phenylalanine hydroxylase maps to 12q22-q24.1 in the human genome; and spans 
about 90 kb of genomic DNA with 13 exons and 12 introns of varying sizes (Kwok 
et al 1985; Lidsky et al 1985; DiLella et al 1986). The heterogeneity observed in PKU 
populations results from more than 60 mutations characterized so far that affect the 
expression of PAH gene (Eisensmith and Woo 1992). The nature of these mutations 
determines the level of expression and the residual PAH activity observed in vitro or 
in vivo. Higher levels of residual activity should lead to milder forms of PKU. The 
genetics of PKU is, however, complicated by the dimeric subunit nature of the PAH 
protein. Therefore, the phenotypic outcome of a mutation in a compound heterozygote 
will be determined by the effect of these mutations on the overall conformation of 
the ultimate PAH dimer formed. It would therefore be helpful to genotype the PKU 
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alleles so that dietary management and genetic counselling would be more meaningful 
to PKU patients. 
The population in the USA is of diverse ethnic backgrounds with the majority 
being of European descent. Therefore, the frequency of PKU mutations observed in 
the USA would vary depending upon the ethnic origin of population under study. 
This study was undertaken to determine the frequency of 12 PKU mutations in the 
midwest region of the USA. The panel of 12 mutations studied has been found to be 
prevalent in the European population (Guldberg et al 1993). 
MATERIALS A N D  M E T H O D S  
Patients." The P K U  patients and their family members enrolled in this study were 
from Illinois, Michigan and Minnesota from the midwest region of the USA. Affected 
siblings of the PKU patients, with the same genotype, were not included in determining 
the frequency of each mutation. The PKU patients were diagnosed and classified 
according to the standard clinical criteria. 
Mutat ion analysis: Dried blood spots were received from the participating clinics 
and were used as a source of DNA for polymerase chain reaction (PCR)-based 
amplification of specific regions of the PAH gene. PCR was carried out in 100#1 
volume under standard conditions that included 30 cycles of denaturation at 94°C 
for 30s, annealing at Tm -4°C ,  and extension at 72°C for 30s. At the end of 30 
cycles a final extension reaction was carried out at 72°C for 7 rain. The amplified 
DNA fragments were denatured and blotted in duplicate on nitrocellulose membrane 
using slot-blot or dot-blot apparatus. The presence of specific PKU mutations was 
analysed by hybridization of duplicate blots to 32p-labelled allele-specific oligonucleo- 
tides under stringent conditions. The hybridized blots were exposed to X-ray film 
and autoradiographed. 
RESULTS A N D  DISCUSSION 
Genotype analysis of PKU patients has resulted in identification of more than 60 
mutations so far and new mutations are constantly being identified. Recently, 
Guldberg et al (1993) have reported identification of 99% of the mutations in 308 
Danish PKU chromosomes. Four  mutations, IVS-12nt 1 (g-~a), arg408-~trp,  
tyr414 -~ cys and IVS-10 nt546 (gg -~ ag) accounted for 70% of all the PKU mutations 
in the Danish study. The homogeneous nature of the population thus facilitates 
mutation analysis. The results of mutation analysis in the midwest region of the USA 
are listed in Table 1. Analysis of 12 mutations in PKU patients revealed that we 
could detect 56.5% (129/228) of all the mutant chromosomes. In terms of determining 
both mutant alleles, 35% of the PKU patients were completely genotyped. About 
9.4% of the patients were homozygous for arg408 -~ trp mutation, whereas others 
with arg408 -~ trp mutation on one allele were compound heterozygotes for another 
PKU mutation. The genotype observed in PKU patients was also tested in other 
family members when available. 
The genotype analysis of PKU patients from the midwest region has offered a 
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Table 1 Frequency of 12 mutations a in 228 P K U  chromosomes in 
the midwest region of  the U S A  
Mutation No. of alleles Frequency Danish study b 
Arg408 --* Trp 51 0.224 0.182 
IVS10 G ~ A 29 0.127 0.052 
IVS12 G ~ A 15 0.066 0.373 
Tyr414 ~ Cys 11 0.048 0.101 
Arg261 ~ Gin 10 0.044 0.016 
Pro281 ~ Leu 5 0.021 0.013 
Glu280 ~ Lys 3 0.013 0.029 
Argl 11 -~ Ter 2 0.008 0.0003 
Gly272 -~ Ter 2 0.008 0.016 
Ile94delATC 1 0.004 Not reported 
~None of the alleles tested carried arg158--* gin or leu311 ~ pro mutation 
bGuldberg et al (1993) 
different experience from that involving mutation analysis in PKU subjects from 
across the US subcontinent (Kaul et al, unpublished data from maternal P K U  
collaborative study). Only 36% of the P K U  chromosomes could be genotyped in the 
collaborative study compared to the 56.5% characterized in the present study. Our 
data suggest that the PKU mutation analysis in the USA population will be important 
but more difficult than the Danish experience. We are currently in the process of 
characterizing other mutations in PKU chromosomes that did not carry any of the 
12 mutations. Such a study will be important in establishing the genotype-phenotype 
correlation in these patients. 
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